Hamza Khoudari,Abdalla Shoaib,Muhammad Nashatizadeh et al.
Hamza Khoudari et al.
Anti-BCMA CAR T-cell therapy, specifically ciltacabtagene autoleucel, has significantly improved outcomes for relapsed/refractory multiple myeloma (RRMM). While early-onset immune-effector cell-associated neurotoxicity syndrome (ICANS) is a...
Richter-like transformation of CLL/SLL after a temporary hold of ibrutinib: A case report [0.03%]
伊布替尼治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤暂停使用后出现里特尔转化的1例报告
Tung-Lin Chiang,John Frater,Amanda Cashen
Tung-Lin Chiang
Bruton tyrosine kinase (BTK) inhibitors are used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), providing survival benefits over traditional chemoimmunotherapy. Richter transformation is the transformation of CL...
Systemic, asymptomatic skeletal muscle infiltration by MALT lymphoma: Defining a 'silent infiltrator' phenotype with 18F-FDG PET/CT [0.03%]
系统性无症状的粘膜相关淋巴组织结外边缘区淋巴瘤肌肉浸润：使用正电子发射断层扫描/X线计算机体层摄影术定义“沉默浸润者”型
Yasuyuki Takahashi,Ken Naganuma,Yuka Tanaka et al.
Yasuyuki Takahashi et al.
We report a rare phenotype of Stage IV extranodal marginal zone lymphoma (MALT lymphoma) manifesting as diffuse, asymptomatic skeletal muscle and bone marrow infiltration in a 60-year-old female. Despite a high tumor burden and intense ¹⁸...
Acute liver failure and severe lactic acidosis as initial manifestations of primary intestinal diffuse large B-cell lymphoma: Case report [0.03%]
原发性肠道弥漫大B细胞淋巴瘤急性肝衰竭和严重乳酸酸中毒的初始表现：病例报告
Hideki Mori,Shiro Miura,Momoko Soeda et al.
Hideki Mori et al.
Diffuse large B-cell lymphoma (DLBCL) typically presents with lymphadenopathy or extranodal masses, but rarely, predominantly as scattered case reports, as acute liver failure (ALF) with severe lactic acidosis. We report a 79-year-old man w...
Clinical and etiological profile of anemia in a clinical hematology department of North Africa : A cross-sectional study [0.03%]
北非临床血液科贫血患者的临床和病因学特征：一项横断面研究
Wiem Boufrikha,Sirine Ben Salem,Nourhene Mazhoud et al.
Wiem Boufrikha et al.
Anemia, a major public health concern impacting physical performance and morbidity, requires etiological assessment as iron deficiency anemia (IDA, 55.7%) may mask hematologic malignancies. This 2022 cross-sectional study at Monastir's Hema...
Meta-analysis of clinical efficacy and safety of decitabine combined with CAG regimen in the treatment of acute myeloid leukemia in the elderly [0.03%]
地西他滨联合小剂量阿糖胞苷、阿霉素和戈利木单抗方案治疗老年急性髓系白血病的临床疗效及安全性meta分析
Yanxia He,Lili Zhang,Mengmeng Liu et al.
Yanxia He et al.
Objective: To systematically evaluate the clinical efficacy and safety of decitabine (DAC) combined with CAG regimen in the treatment of elderly patients with acute myeloid leukemia (AML) using meta-analysis. ...
Gemcitabine, dexamethasone and cisplatin with or without rituximab is highly effective as a mobilization regimen in relapsed or refractory lymphoma [0.03%]
吉西他滨、地塞米松和顺铂联合或不联合利妥昔单抗可高效动员复发或难治性淋巴瘤患者的外周血干细胞
Vincent T Taillefer,Marianne Emond,Marie-Hélène Leblanc et al.
Vincent T Taillefer et al.
Introduction: A combination of Gemcitabine, Dexamethasone and Cisplatin (GDP) with or without rituximab (±R) is an outpatient treatment widely used for relapsed or refractory (R/R) lymphoma. Limited data are available on...
Leukocytosis and a JAK2 mutation: The importance of expertise in somatic variant interpretation [0.03%]
白细胞增多和JAK2突变的重要性：体细变异解释中的专业知识
Christian J Puzo,Karl Hager,Michal Rose et al.
Christian J Puzo et al.
This case details a patient presenting with a history of chronic leukocytosis with isolated eosinophilia, who was found to have a JAK2 G571S mutation by a next generation sequencing (NGS) panel for myeloproliferative neoplasm driver mutatio...
Survival predictors in Vietnamese elderly AML patients treated with decitabine: Real-world evidence from a low- and middle-income country [0.03%]
地塞米坦治疗越南老年急性髓系白血病患者的生存预测因素：来自中低收入国家的真实世界证据
Ha Thanh Nguyen,Quoc Khanh Bach,Quoc Nhat Nguyen et al.
Ha Thanh Nguyen et al.
Background: Hypomethylating agents such as decitabine represent a key treatment option for elderly acute myeloid leukemia (AML) patients who are unfit for intensive chemotherapy. However, real-world evidence from low- and...
The synergistic tumor suppressor effect of CDK4/6 inhibitors and BRD4 inhibitors in acute myeloid leukemia [0.03%]
CDK4/6抑制剂和BRD4抑制剂在急性髓系白血病中的协同抑癌作用
Kaiqiong Liao,Chong Guo,Min Zhang et al.
Kaiqiong Liao et al.
Objective: The objective of this research is to explore the anti-leukemic properties of CDK4/6 inhibitors when used alongside BET inhibitors for treating acute myeloid leukemia (AML), as well as to clarify the molecular m...